Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 1.59B |
| Revenue (ttm) | 263.50M |
| Net Income (ttm) | -390.98M |
| Shares Out | 411.96M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,268,929 |
| Open | 3.800 |
| Previous Close | 3.745 |
| Day's Range | 3.730 - 3.865 |
| 52-Week Range | 1.639 - 4.570 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 8.89 (+129.72%) |
| Earnings Date | Feb 24, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $8.89, which is an increase of 129.72% from the latest price.
News
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B pe...
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarc...
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N...
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate
Iovance Biotherapeutics: Bright Prospects For 2026
Iovance Biotherapeutics is reaffirmed as a Buy, driven by Amtagvi's strong efficacy and blockbuster potential in melanoma and lung cancer. IOVA targets significant market expansion, with lung cancer r...
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode
Iovance Biotherapeutics remains a Sell due to ongoing dilution risk, sub-consensus revenue, and only modest margin improvements. Q3 revenue landed in the base case at $68 million, missing estimates, w...
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. ( IOVA) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications ...
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stoc...
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $10...
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring w...
Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reite...
Here's why Iova stock surged 32% today and why the rally might not be over
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran...
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revi...
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
LOS ANGELES , July 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violatio...
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focu...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.
SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...